{"id":4225,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2008-06-20","marketCap":1973.13,"name":"Iovance Biotherapeutics Inc","phone":"16502607120","outstanding":255.92,"symbol":"IOVA","website":"https://www.iovance.com/","industry":"Biotechnology"},"price":10.425,"year":2024,"month":8,"day":14,"weekday":"Wednesday","title":"Potential growth prospects and expansion strategies for Iovance Biotherapeutics Inc stock in its respective industry","date":"2024-08-14","url":"/posts/2024/08/14/IOVA","content":[{"section":"1. Expanding Pipeline","text":"Iovance Biotherapeutics Inc has a robust pipeline of potential cancer immunotherapies, including its lead product candidate LN-144, which is under investigation for the treatment of advanced melanoma and cervical cancer. The company also has other candidates in early-stage development targeting various types of cancer. The expansion of the pipeline provides multiple growth opportunities for the company."},{"section":"2. Increasing Market Demand","text":"The global market for cancer immunotherapies is expected to experience significant growth in the coming years. With the increasing prevalence of cancer and the demand for more effective treatments, Iovance Biotherapeutics Inc is well-positioned to capitalize on the expanding market opportunities. The company's innovative approach to cancer treatment through Tumor-Infiltrating Lymphocytes (TIL) therapy gives it a distinct advantage in meeting the demand for personalized and targeted therapies."},{"section":"3. Strategic Partnerships and Collaborations","text":"Iovance Biotherapeutics Inc has strategically partnered with renowned academic institutions and research organizations to advance its scientific research and development efforts. Collaborations with leading cancer centers and key opinion leaders in the field provide access to expertise, resources, and patient populations, which can accelerate the clinical development of its product candidates. These partnerships also enhance the company's reputation and increase its visibility in the industry."},{"section":"4. Regulatory Approvals and Commercialization","text":"As Iovance Biotherapeutics Inc progresses through clinical trials and achieves positive results, obtaining regulatory approvals for its product candidates becomes a key driver of growth. Successful completion of clinical trials and subsequent approvals from regulatory authorities will allow the company to commercialize its therapies and generate revenues. The company's focus on developing therapies for orphan indications may also provide opportunities for expedited regulatory pathways, facilitating faster market entry."},{"section":"5. Global Expansion and Market Penetration","text":"Iovance Biotherapeutics Inc is currently focused on the U.S. market but has the potential to expand its presence globally. As the company receives regulatory approvals and commercializes its therapies in the United States, it can explore international markets and partnerships to further drive growth. Expanding into regions with high unmet medical needs and a favorable regulatory environment can provide additional revenue streams and market opportunities for the company."},{"section":"6. Continued Research and Innovation","text":"Innovation is crucial in the highly competitive biotechnology industry, and Iovance Biotherapeutics Inc recognizes the importance of continued research and development. The company invests in scientific advancements, leveraging new technologies, and exploring novel applications of TIL therapy. By staying at the forefront of scientific discoveries and technological advancements, Iovance Biotherapeutics Inc can maintain a competitive edge and drive future growth."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1723573907,"headline":"Industry Analysts Just Made A Sizeable Upgrade To Their Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Revenue Forecasts","id":129349218,"image":"https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","symbol":"IOVA","publisher":"Yahoo","summary":"Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) shareholders will have a reason to smile today, with the analysts making...","url":"https://finance.yahoo.com/news/industry-analysts-just-made-sizeable-183147424.html"},{"category":"company","date":1723466220,"headline":"10 Health Care Stocks With Whale Alerts In Today's Session","id":129314415,"image":"","symbol":"IOVA","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3597431596"},{"category":"company","date":1723460456,"headline":"3 US Growth Companies With High Insider Ownership Growing Earnings Up To 68%","id":129314396,"image":"https://media.zenfs.com/en/simply_wall_st__316/ee047812921f935c11e8b8a18a28c857","symbol":"IOVA","publisher":"Yahoo","summary":"As U.S. markets navigate a rollercoaster of volatility, with major indices experiencing both significant gains and losses, investors are increasingly seeking stable opportunities amidst the turbulence. One promising strategy is to focus on growth companies with high insider ownership, as this often indicates strong confidence from those closest to the business.","url":"https://finance.yahoo.com/news/3-us-growth-companies-high-110056177.html"},{"category":"company","date":1723456620,"headline":"Biotech Alert: Searches spiking for these stocks today","id":129311945,"image":"","symbol":"IOVA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3597235970"},{"category":"company","date":1723453620,"headline":"Iovance Biotherapeutics Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)","id":129311946,"image":"","symbol":"IOVA","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3597176748"},{"category":"company","date":1723444200,"headline":"Analysts Are Bullish on Top Healthcare Stocks: Pacira Pharmaceuticals (PCRX), Iovance Biotherapeutics (IOVA)","id":129311947,"image":"","symbol":"IOVA","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3597017320"},{"category":"company","date":1723444140,"headline":"Truist Financial Sticks to Its Buy Rating for Iovance Biotherapeutics (IOVA)","id":129311948,"image":"","symbol":"IOVA","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3597014866"},{"category":"company","date":1723377420,"headline":"Iovance Biotherapeutics Poised for Strong Market Position and Financial Growth: Buy Rating Affirmed","id":129306407,"image":"","symbol":"IOVA","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3596405736"},{"category":"company","date":1723366800,"headline":"Iovance's Tumor-Fighting TILs Are Just Warming Up (Rating Upgrade)","id":129304041,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1016571530/image_1016571530.jpg?io=getty-c-w1536","symbol":"IOVA","publisher":"SeekingAlpha","summary":"Iovance's Q2 2024 revenue of $31.1 million surpassed analyst expectations. Check out why I upgrade IOVA stock from hold to buy.","url":"https://seekingalpha.com/article/4713498-iovance-tumor-fighting-tils-just-warming-up-rating-upgrade"},{"category":"company","date":1723293113,"headline":"Iovance Biotherapeutics Second Quarter 2024 Earnings: Beats Expectations","id":129292473,"image":"https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","symbol":"IOVA","publisher":"Yahoo","summary":"Iovance Biotherapeutics ( NASDAQ:IOVA ) Second Quarter 2024 Results Key Financial Results Revenue: US$31.1m (up by...","url":"https://finance.yahoo.com/news/iovance-biotherapeutics-second-quarter-2024-123153076.html"},{"category":"company","date":1723220612,"headline":"Why Iovance Biotherapeutics Shares Are Soaring Today","id":129267972,"image":"https://g.foolcdn.com/editorial/images/786692/break-through-ceiling.jpg","symbol":"IOVA","publisher":"Yahoo","summary":"The biopharma company is proving its recently approved cancer therapy is marketable.","url":"https://www.fool.com/investing/2024/08/09/why-iovance-biotherapeutics-shares-are-soaring-tod/?source=eptyholnk0000202\u0026amp;utm_source=yahoo-host-full\u0026amp;utm_medium=feed\u0026amp;utm_campaign=article\u0026amp;referring_guid=134125b3-b6a6-430a-aa91-a2ad0334e765\u0026amp;.tsrc=rss"},{"category":"company","date":1723210020,"headline":"Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View","id":129267975,"image":"https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","symbol":"IOVA","publisher":"Yahoo","summary":"Iovance (IOVA) reports better-than-expected second-quarter results. Shares price rises on the back of encouraging product revenue guidance issued by management for 2024 and 2025.","url":"https://finance.yahoo.com/news/iovance-iova-q2-earnings-beat-132700063.html"},{"category":"company","date":1723206960,"headline":"Iovance Biotherapeutics: A Strong Buy on Robust Financials and Promising Market Prospects","id":129265758,"image":"","symbol":"IOVA","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3593621606"},{"category":"company","date":1723204380,"headline":"Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday","id":129264143,"image":"","symbol":"IOVA","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3594207990"},{"category":"company","date":1723202700,"headline":"Why Is Iovance Bio (IOVA) Stock Up 18% Today?","id":129265760,"image":"","symbol":"IOVA","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3594171203"},{"category":"company","date":1723192200,"headline":"Iovance soars 17% as 2024 and 2025 revenue guidance well above consensus","id":129265761,"image":"","symbol":"IOVA","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3593967454"},{"category":"company","date":1723189080,"headline":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Collegium Pharmaceutical (COLL), Scholar Rock Holding (SRRK) and Iovance Biotherapeutics (IOVA)","id":129262816,"image":"","symbol":"IOVA","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3593910175"},{"category":"company","date":1723186620,"headline":"Iovance Biotherapeutics: A Strong Buy on Robust Earnings and Promising Clinical Progress","id":129265764,"image":"","symbol":"IOVA","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3593871476"},{"category":"company","date":1723183320,"headline":"Iovance Biotherapeutics price target lowered by $2 at Baird, here's why","id":129265766,"image":"","symbol":"IOVA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3593823174"},{"category":"company","date":1723176480,"headline":"Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket","id":129261373,"image":"","symbol":"IOVA","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3593747100"},{"category":"company","date":1723176466,"headline":"Iovance Biotherapeutics, Inc. 2024 Q2 - Results - Earnings Call Presentation","id":129255364,"image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","symbol":"IOVA","publisher":"SeekingAlpha","summary":"The following slide deck was published by Iovance Biotherapeutics, Inc.","url":"https://seekingalpha.com/article/4712626-iovance-biotherapeutics-inc-2024-q2-results-earnings-call-presentation"},{"category":"company","date":1723171680,"headline":"Iovance Biotherapeutics (IOVA) Gets a Buy from Barclays","id":129265769,"image":"","symbol":"IOVA","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3593700820"},{"category":"company","date":1723152610,"headline":"Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates","id":129245865,"image":"https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85","symbol":"IOVA","publisher":"Yahoo","summary":"Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 8.11% and 37.73%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?","url":"https://finance.yahoo.com/news/iovance-biotherapeutics-iova-reports-q2-213010508.html"},{"category":"company","date":1723149126,"headline":"Iovance Biotherapeutics, Inc. (IOVA) Q2 2024 Earnings Call Transcript","id":129246568,"image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","symbol":"IOVA","publisher":"SeekingAlpha","summary":"Iovance Biotherapeutics, Inc. (NASDAQ:NASDAQ:IOVA) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ETCompany ParticipantsSara Pellegrino â Senior...","url":"https://seekingalpha.com/article/4712460-iovance-biotherapeutics-inc-iova-q2-2024-earnings-call-transcript"},{"category":"company","date":1723148685,"headline":"Iovance Biotherapeutics: Q2 Earnings Snapshot","id":129245866,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"IOVA","publisher":"Yahoo","summary":"SAN CARLOS, Calif. AP) — Iovance Biotherapeutics Inc. IOVA) on Thursday reported a loss of $97.1 million in its second quarter.","url":"https://finance.yahoo.com/news/iovance-biotherapeutics-q2-earnings-snapshot-202445952.html"},{"category":"company","date":1723147260,"headline":"Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024","id":129245867,"image":"https://media.zenfs.com/en/globenewswire.com/cedc32b016b8dc2392e47b634c25fda0","symbol":"IOVA","publisher":"Yahoo","summary":"Strong Momentum Continues for Amtagvi™ (Lifileucel) U.S. Launch with $31.1 Million in Total 2Q24 Revenue Total Product Revenue Guidance of $53-$55 Million for 3Q24, $160-$165 Million for FY24, and $450-$475 Million for FY25 SAN CARLOS, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, to","url":"https://finance.yahoo.com/news/iovance-biotherapeutics-reports-financial-results-200100496.html"},{"category":"company","date":1723144949,"headline":"Iovance Biotherapeutics : Corporate Presentation","id":129245582,"image":"","symbol":"IOVA","publisher":"Finnhub","summary":"Corporate Overview August 2024 © 2024, Iovance Biotherapeutics, Inc. ...","url":"https://finnhub.io/api/news?id=389a77836e5aa41c5b719030563a14348b89b26f11e60ca8471223e7953fe2a8"},{"category":"company","date":1723111560,"headline":"Iovance Biotherapeutics: A Buoyant Future Backed by Strong Sales Guidance and Q2 Performance","id":129265773,"image":"","symbol":"IOVA","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3593472709"},{"category":"company","date":1723111320,"headline":"IOVA September 27th Options Begin Trading","id":129239070,"image":"","symbol":"IOVA","publisher":"Stock Options Channel","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3592082953"},{"category":"company","date":1723111200,"headline":"IOVA Stock Earnings: Iovance Biotherapeutics Beats EPS, Beats Revenue for Q2 2024","id":129265774,"image":"","symbol":"IOVA","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3593458080"},{"category":"company","date":1723089300,"headline":"Iovance Biotherapeutics Inc (IOVA) Q2 2024 Earnings: EPS of -$0.34, Revenue of $31. ...","id":129265776,"image":"","symbol":"IOVA","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3592720244"},{"category":"company","date":1723088280,"headline":"What the Options Market Tells Us About Iovance Biotherapeutics","id":129265777,"image":"","symbol":"IOVA","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3592681978"},{"category":"company","date":1723087080,"headline":"Iovance Biotherapeutics GAAP EPS of -$0.34 beats by $0.01, revenue of $31.1M beats by $6.54M","id":129265778,"image":"","symbol":"IOVA","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3592641970"},{"category":"company","date":1723086900,"headline":"Iovance Biotherapeutics reports Q2 EPS (34c), consensus (35c)","id":129265779,"image":"","symbol":"IOVA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3592636721"},{"category":"company","date":1723079040,"headline":"Iovance Biotherapeutics options imply 15.7% move in share price post-earnings","id":129239071,"image":"","symbol":"IOVA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3592399179"},{"category":"company","date":1722995700,"headline":"Iovance Biotherapeutics put volume heavy and directionally bearish","id":129239072,"image":"","symbol":"IOVA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3590432309"},{"category":"company","date":1722952814,"headline":"Kronos Bio, Inc. (KRON) Expected to Beat Earnings Estimates: Should You Buy?","id":129179065,"image":"https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781","symbol":"IOVA","publisher":"Yahoo","summary":"Kronos Bio (KRON) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.","url":"https://finance.yahoo.com/news/kronos-bio-inc-kron-expected-140014025.html"},{"category":"company","date":1722951002,"headline":"AquaBounty Technologies, Inc. (AQB) Reports Q2 Loss, Tops Revenue Estimates","id":129184881,"image":"https://media.zenfs.com/en/zacks.com/b9775f315e7b6c4ada6e36d0048a929a","symbol":"IOVA","publisher":"Yahoo","summary":"AquaBounty Technologies (AQB) delivered earnings and revenue surprises of -67.74% and 80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?","url":"https://finance.yahoo.com/news/aquabounty-technologies-inc-aqb-reports-133002832.html"},{"category":"company","date":1722520883,"headline":"Iovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?","id":129071312,"image":"https://media.zenfs.com/en/zacks.com/4f1a8d86cead9f96536efb147945dcc9","symbol":"IOVA","publisher":"Yahoo","summary":"Iovance Biotherapeutics (IOVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.","url":"https://finance.yahoo.com/news/iovance-biotherapeutics-iova-expected-beat-140123246.html"},{"category":"company","date":1722466800,"headline":"Artisan Small Cap Fund Q2 2024 Commentary","id":129053877,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/523155194/image_523155194.jpg?io=getty-c-w1536","symbol":"IOVA","publisher":"SeekingAlpha","summary":"Artisan Small Cap Fund portfolio generated a negative absolute return and underperformed the Russell 2000Â® Growth Index in Q2 2024. Click here to read the full commentary","url":"https://seekingalpha.com/article/4708916-artisan-small-cap-fund-q2-2024-commentary"},{"category":"company","date":1722425384,"headline":"Bullish Iovance Biotherapeutics Insiders Loaded Up On US$74.9m Of Stock","id":129035595,"image":"https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","symbol":"IOVA","publisher":"Yahoo","summary":"Multiple insiders secured a larger position in Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) shares over the last 12...","url":"https://finance.yahoo.com/news/bullish-iovance-biotherapeutics-insiders-loaded-112944906.html"},{"category":"company","date":1722418260,"headline":"Iovance Biotherapeutics Attracted a Downgrade. Is It Time to Sell?","id":129035596,"image":"https://g.foolcdn.com/editorial/images/785006/investor-dark-room-devices-getty.jpg","symbol":"IOVA","publisher":"Yahoo","summary":"Find out how concerned investors should be about setbacks for this company's revolutionary new cancer therapies.","url":"https://www.fool.com/investing/2024/07/31/iovance-biotherapeutics-attracts-a-downgrade-is-it/?source=eptyholnk0000202\u0026amp;utm_source=yahoo-host-full\u0026amp;utm_medium=feed\u0026amp;utm_campaign=article\u0026amp;referring_guid=ba25fff8-08f2-40f2-bbcd-a13d7cda037a\u0026amp;.tsrc=rss"}]}